R-P MYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover R-p Mycin, and what generic alternatives are available?
R-p Mycin is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in R-P MYCIN is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for R-p Mycin
A generic version of R-P MYCIN was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for R-P MYCIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 4,179 |
Formulation / Manufacturing: | see details |
DailyMed Link: | R-P MYCIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for R-P MYCIN
US Patents and Regulatory Information for R-P MYCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solvay | R-P MYCIN | erythromycin | TABLET, DELAYED RELEASE;ORAL | 061659-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |